AstraZeneca announces new £120m Macclesfield site

AstraZeneca sign AstraZeneca is the UK's second largest drugs company

Related Stories

Pharmaceutical giant AstraZeneca are to open a £120m site in Cheshire to continue manufacturing a prostate cancer treatment drug in the area.

The development in Macclesfield will produce Zoladex, which has been made locally for more than 25 years.

The company said the site, due to open in 2016, would secure 300 jobs.

In March, the company announced the closure of the nearby Alderley Park research and development unit with the loss of about 700 jobs.

David Smith, executive vice-president for operations at AstraZeneca, said that having "considered a number of options globally, we believe it is the right choice to build the new facility in Macclesfield".

He said the town had been "home to Zoladex manufacturing - and the expertise that goes along with it - for many years".

The company has previously announced the closure of the Alderley Park unit and a laboratory in Brixham, Devon, alongside the building of a new £330m global headquarters for the firm in Cambridge.

The Anglo-Swedish firm employs over 6,000 people in the UK and is the second largest drugs company in the UK after GlaxoSmithKline.

More on This Story

Related Stories

The BBC is not responsible for the content of external Internet sites

More England stories


Features & Analysis

Elsewhere on the BBC

  • TravelAround the world

    BBC Travel takes a look at the most striking images from the past seven days


  • A bicycle with a Copenhagen WheelClick Watch

    The wheel giving push bikes an extra boost by turning them into smart electric hybrids

Try our new site and tell us what you think. Learn more
Take me there

Copyright © 2015 BBC. The BBC is not responsible for the content of external sites. Read more.

This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.